# LAPTM4B

## Overview
LAPTM4B, or lysosomal-associated protein transmembrane 4 beta, is a gene that encodes a tetratransmembrane protein involved in various cellular processes, including lysosomal targeting and signal transduction. The protein, also referred to as LAPTM4B, is characterized by its four transmembrane domains and is primarily localized to late endosomes and lysosomes. It plays a significant role in modulating epidermal growth factor receptor (EGFR) signaling and is implicated in the regulation of cellular growth and survival pathways. The gene has garnered attention due to its association with increased cancer susceptibility and its potential as a therapeutic target in oncology (Liu2004Structure; Meng2013LAPTM4Bgene; Tan2015LAPTM4B).

## Structure
The LAPTM4B protein is a tetratransmembrane protein with a molecular mass of 35 kDa, consisting of 317 amino acids. It features four highly conserved hydrophobic transmembrane domains, which form two extracellular loops, a cytoplasmic loop, and intracellular amino and carboxyl tails (Liu2004Structure). The transmembrane regions are located at amino acids 117-133, 163-179, 200-216, and 243-259 (Liu2004Structure). The protein has a proline-rich motif (PXXP) at the N-terminal region, suggesting it could bind to SH3 domains, and contains typical lysosomal targeting signals (YXX motifs) at the C-terminal region (Liu2004Structure; Shao2003Molecular).

LAPTM4B undergoes post-translational modifications, including phosphorylation at eight sites and N-myristoylation at four sites. It also has one N-glycosylation site (Liu2004Structure; Shao2003Molecular). The protein exists in multiple isoforms, primarily LAPTM4B-35 and LAPTM4B-24, which arise from alternative translation initiation sites (Liu2004Structure; Shao2003Molecular). The 24-kDa isoform results from translation initiation at a downstream ATG, and the 26-kDa protein may be a modified form of the 24-kDa isoform (Shao2003Molecular). The protein's structure and modifications suggest its involvement in lysosomal targeting and signal transduction.

## Function
LAPTM4B is an endosomal protein that plays a crucial role in regulating epidermal growth factor receptor (EGFR) signaling, lysosomal sorting, and degradation. It is involved in modulating the trafficking of EGFR by inhibiting its movement to lysosomes, thereby slowing down its degradation. This regulation is essential for maintaining cellular signaling balance, as it enhances and prolongs EGFR and AKT signaling pathways, which are critical for cell growth and survival (Tan2015LAPTM4B).

LAPTM4B interacts with the endosomal PIP kinase, PIPKIci5, and is regulated by PtdIns(4,5)P2. This interaction is vital for its function in controlling EGFR sorting and degradation. LAPTM4B also interacts with the E3 ubiquitin ligase Nedd4, which facilitates the ubiquitination of Hrs, a key subunit of the ESCRT-0 complex involved in EGFR sorting. This interaction stabilizes endosomal EGFR signaling by inhibiting Hrs's ability to interact with ubiquitylated cargo proteins (Tan2015Emerging; Tan2015LAPTM4B).

LAPTM4B is localized to late endosomes and lysosomes, where it colocalizes with markers such as CD63, LAMP1, and EEA1, indicating its distribution throughout the endosomal system (Tan2015LAPTM4B). Its role in these cellular processes highlights its importance in maintaining cellular homeostasis and signaling in healthy human cells.

## Clinical Significance
The LAPTM4B gene is clinically significant due to its association with increased susceptibility to various cancers. Polymorphisms in LAPTM4B, particularly the LAPTM4B*2 allele, have been linked to a higher risk of developing multiple cancers, including liver, breast, gastric, ovarian, and endometrial cancers (Mo2014LAPTM4B; Meng2013LAPTM4Bgene). In primary liver cancer, the LAPTM4B*2 allele is associated with a significantly increased risk, with genotypes *1/2 and *2/2 being more prevalent in cancer patients compared to healthy controls (Wang2012Relationship).

LAPTM4B overexpression is correlated with poor prognosis and increased tumor aggressiveness in several cancers, such as hepatocellular carcinoma (HCC), lung, colon, and breast cancers (Yang2010Overexpression; Liu2009LAPTM4B‐35). The LAPTM4B-35 protein, encoded by this gene, promotes cell proliferation, migration, and invasion, contributing to the malignant phenotype of cancer cells (Liu2009LAPTM4B‐35). It also plays a role in chemotherapy resistance, particularly in breast cancer, by enhancing drug efflux and activating the PI3K/AKT signaling pathway (Meng2016LAPTM4B:). These findings suggest that LAPTM4B could be a potential target for novel anticancer therapies (Meng2013LAPTM4Bgene).

## Interactions
LAPTM4B interacts with several proteins, playing a significant role in various cellular processes. It has been shown to interact with RhoA, a small GTPase involved in cytoskeleton organization. LAPTM4B stabilizes RhoA by inhibiting its degradation through the ubiquitin-proteasome pathway, which is crucial for maintaining RhoA protein levels in osteosarcoma cells (Yan2023miR137–LAPTM4B).

In non-small cell lung cancer (NSCLC), LAPTM4B interacts with SLC7A11, a component of the cystine-glutamate antiporter system Xc-. This interaction suppresses the ubiquitin-proteasome degradation of SLC7A11, thereby stabilizing it and counteracting ferroptosis, a form of regulated cell death (Yan2024LAPTM4B).

LAPTM4B also interacts with the leucine transporter 4F2hc in late endosomal compartments. This interaction is regulated by ceramide and is crucial for mTORC1 signaling, which is involved in nutrient sensing and cellular growth. The interaction between LAPTM4B and 4F2hc is enhanced by ceramide, highlighting the role of LAPTM4B in amino acid transporter interaction and nutrient signaling (Zhou2018A).

Additionally, LAPTM4B modulates EGFR signaling by interacting with PIPKIci5, a phosphatidylinositol phosphate kinase. This interaction is regulated by PtdIns(4,5)P2 and is important for EGFR trafficking and degradation, influencing cell survival and proliferation (Tan2015LAPTM4B).


## References


[1. (Mo2014LAPTM4B) Cuiju Mo, Yu Lu, Yan Deng, Jian Wang, Li Xie, Taijie Li, Yu He, Qiliu Peng, Xue Qin, and Shan Li. Laptm4b polymorphism increases susceptibility to multiple cancers in chinese populations: a meta-analysis. BMC Genetics, April 2014. URL: http://dx.doi.org/10.1186/1471-2156-15-48, doi:10.1186/1471-2156-15-48. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1471-2156-15-48)

[2. (Tan2015Emerging) Xiaojun Tan, Narendra Thapa, Suyong Choi, and Richard A. Anderson. Emerging roles of ptdins(4,5)p2 – beyond the plasma membrane. Journal of Cell Science, 128(22):4047–4056, November 2015. URL: http://dx.doi.org/10.1242/jcs.175208, doi:10.1242/jcs.175208. This article has 84 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1242/jcs.175208)

[3. (Shao2003Molecular) Gen-Ze Shao, Rou-Li Zhou, Qing-Yun Zhang, Ye Zhang, Jun-Jian Liu, Jing-An Rui, Xue Wei, and Da-Xiong Ye. Molecular cloning and characterization of laptm4b, a novel gene upregulated in hepatocellular carcinoma. Oncogene, 22(32):5060–5069, August 2003. URL: http://dx.doi.org/10.1038/sj.onc.1206832, doi:10.1038/sj.onc.1206832. This article has 133 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/sj.onc.1206832)

[4. (Tan2015LAPTM4B) Xiaojun Tan, Yue Sun, Narendra Thapa, Yihan Liao, Andrew C Hedman, and Richard A Anderson. Laptm4b is a ptdins(4,5)p 2 effector that regulates egfr signaling, lysosomal sorting, and degradation. The EMBO Journal, 34(4):475–490, January 2015. URL: http://dx.doi.org/10.15252/embj.201489425, doi:10.15252/embj.201489425. This article has 69 citations.](https://doi.org/10.15252/embj.201489425)

[5. (Zhou2018A) Kecheng Zhou, Andrea Dichlberger, Hector Martinez-Seara, Thomas K. M. Nyholm, Shiqian Li, Young Ah Kim, Ilpo Vattulainen, Elina Ikonen, and Tomas Blom. A ceramide-regulated element in the late endosomal protein laptm4b controls amino acid transporter interaction. ACS Central Science, 4(5):548–558, May 2018. URL: http://dx.doi.org/10.1021/acscentsci.7b00582, doi:10.1021/acscentsci.7b00582. This article has 31 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1021/acscentsci.7b00582)

[6. (Liu2004Structure) Xin-Rong Liu. Structure analysis and expressions of a novel tetratransmembrane protein, lysosoma-associated protein transmembrane 4 β associated with hepatocellular carcinoma. World Journal of Gastroenterology, 10(11):1555, 2004. URL: http://dx.doi.org/10.3748/wjg.v10.i11.1555, doi:10.3748/wjg.v10.i11.1555. This article has 44 citations and is from a poor quality or predatory journal.](https://doi.org/10.3748/wjg.v10.i11.1555)

[7. (Wang2012Relationship) S. Wang, Q-Y Zhang, and R-L Zhou. Relationship between laptm4b gene polymorphism and susceptibility of primary liver cancer. Annals of Oncology, 23(7):1864–1869, July 2012. URL: http://dx.doi.org/10.1093/annonc/mdr538, doi:10.1093/annonc/mdr538. This article has 19 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/annonc/mdr538)

[8. (Yan2024LAPTM4B) Ruyu Yan, Dan Liu, Hongjuan Guo, Minxia Liu, Dongjin Lv, Benny Björkblom, Mingsong Wu, Hongtao Yu, Hao Leng, Bingxiao Lu, Yuxiang Li, Miaomiao Gao, Tomas Blom, and Kecheng Zhou. Laptm4b counteracts ferroptosis via suppressing the ubiquitin-proteasome degradation of slc7a11 in non-small cell lung cancer. Cell Death &amp; Disease, June 2024. URL: http://dx.doi.org/10.1038/s41419-024-06836-x, doi:10.1038/s41419-024-06836-x. This article has 0 citations.](https://doi.org/10.1038/s41419-024-06836-x)

[9. (Meng2013LAPTM4Bgene) Fanling Meng, Huiyan Li, Rouli Zhou, Chang Luo, Yuanlong Hu, and Ge Lou. Laptm4bgene polymorphism and endometrial carcinoma risk and prognosis. Biomarkers, 18(2):136–143, January 2013. URL: http://dx.doi.org/10.3109/1354750X.2012.752526, doi:10.3109/1354750x.2012.752526. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.3109/1354750X.2012.752526)

[10. (Yan2023miR137–LAPTM4B) Ruyu Yan, Dan Liu, Junjie Wang, Minxia Liu, Hongjuan Guo, Jing Bai, Shuo Yang, Jun Chang, Zhihong Yao, Zuozhang Yang, Tomas Blom, and Kecheng Zhou. Mir-137–laptm4b regulates cytoskeleton organization and cancer metastasis via the rhoa-limk-cofilin pathway in osteosarcoma. Oncogenesis, May 2023. URL: http://dx.doi.org/10.1038/s41389-023-00471-5, doi:10.1038/s41389-023-00471-5. This article has 4 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41389-023-00471-5)

[11. (Yang2010Overexpression) Hua Yang, Fuxia Xiong, Xuanhui Wei, Yu Yang, Michael A. McNutt, and Rouli Zhou. Overexpression of laptm4b-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer Letters, 294(2):236–244, August 2010. URL: http://dx.doi.org/10.1016/j.canlet.2010.02.006, doi:10.1016/j.canlet.2010.02.006. This article has 64 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.canlet.2010.02.006)

[12. (Liu2009LAPTM4B‐35) Xinrong Liu, Fuxia Xiong, Xuanhui Wei, Hua Yang, and Rouli Zhou. Laptm4b‐35, a novel tetratransmembrane protein and its pprp motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells. Cancer Science, 100(12):2335–2340, November 2009. URL: http://dx.doi.org/10.1111/j.1349-7006.2009.01346.x, doi:10.1111/j.1349-7006.2009.01346.x. This article has 48 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/j.1349-7006.2009.01346.x)

[13. (Meng2016LAPTM4B:) Y Meng, L Wang, D Chen, Y Chang, M Zhang, J-J XU, R Zhou, and Q-Y Zhang. Laptm4b: an oncogene in various solid tumors and its functions. Oncogene, 35(50):6359–6365, May 2016. URL: http://dx.doi.org/10.1038/onc.2016.189, doi:10.1038/onc.2016.189. This article has 54 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/onc.2016.189)